时 间 | Feb 7-8, 2022

地 点 | Parsippany, NJ Hilton

届时，JDB电子国际研发服务部执行副总裁戴学东博士将进行PROTAC有关的主题演讲分享
。

戴学东博士 JDB电子国际研发服务部执行副总裁

美国麻省理工大学有机化学博士，博士后，深耕于中枢神经系统疾病、传染病和肿瘤疾病化学药物的研发20余载，对药物发现过程中蕴含苗头化合物简直定及优化，以及成功发展到高质量的临床候选化合物有着深刻的理解和丰硕的实际经验
。戴学东博士参加主持研发的药物有已上市药物，如Horizant?/Regnite?
；临床药物，如JNJ-75276617
；临床候选化合物，如Arbaclofen Placarbil，XP21279，XP23829等
。

ExecutiveVP and Head of IDSU (International Discovery Service Unit) at Medicilon,obtained his Ph.D. in organic chemistry at MIT. He is a senior-level expertwith over 20 years of experience focusing on small molecule drug discovery anddevelopment in CNS, infectious disease, and oncology therapy areas. He has deepunderstanding and practical knowledge of drug discovery process, including leadidentification, optimization, and development of high quality clinicalcandidate molecules. Prior to Medicilon, Dr. Dai worked at Janssen, HDBiosciences, GSK, and Xenoportwith a demonstrated successful track record ofprogram leadership and made significant contributions to medicinal chemistryprograms that led to the marketed drug Horizant?/Regnite? and several otherclinical candidates (JNJ-75276617, arbaclofen placarbil, XP21279, and XP23829).

JDB电子国际研发服务部是JDB电子一站式生物医药临床前研发服务平台的沉要组成部门，使命是持续助力药企的国际化，向全球药物研发客户提供高质高效高性价比的合成化学、药物设计、以及新药候选化合物服务，以满足客户在临床前新药钻研的各个化学领域的研发需要，缩短药物研发的周期，降低药物研发的成本
。

目前，JDB电子国际研发服务部占有丰硕海表留学工作布景的治理团队和尝试人员、世界先进水平的合成尝试室、分析尝试室、和配套的高端仪器设备
。为了给客户提供更优质的服务，国际研发服务部紧跟药物设计以及合成的新进展和新技术，如人为智能/机械进建（AI/ML），蛋白降解靶向嵌合体（PROTAC），高活性药物及抗体药物偶联物（ADC），惰性碳氢键直接官能团化，光致氧化还原反映，以及流动化学等
。

The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies.  We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D.

Medicilon International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment.  In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.

JDB电子PROTAC药物发现技术平台汇总了当前盛行的热点的靶标蛋白配体
；成立了宽泛的热点靶向蛋白高度亲和力幼分子及幼分子片段化合物库（TPSM），宽泛的E3衔接酶，高度亲和力的幼分子及幼分子片段（E3SM）
；成立了linker系统,蕴含网络大量拥有宽泛多样性的双官能团衔接体（BF-Linker）
。这些堆集的化合物库能够援手急剧高效的合成大量高活性PROTAC双特异性幼分子，极大地提高选取PROTAC技术进行的药物研发过程
。除了急剧合成之表，我们同时成立和美满的PROTAC生物筛选与测试平台，后续发展到临床前所有阶段
。

Proteolysis Targeting Chimeras (PROTACs) are interesting biology as achemical knock-down approach in a fast and reversible way. Medicilon has established a wide range of popular target proteins withhigh affinity small molecules and small molecule fragment compound libraries, awide range of E3 ligases, and high affinity small molecules and small moleculefragments. We offer these services in any format you like;we can only do the chemical synthesis part for you, only the in vitro and/or invivo part, or we can offer a fully combined package.

JDB电子（股票代码：688202）成立于2004年，总部位于上海，致力于为全球造药企业、钻研机构及科研工作者提供全方位的临床前新药钻研服务
。JDB电子的一站式综合服务以强有力的项目治理和更高效、高性价比的研发服务助力客户加快新药研发过程，服务涵盖医药临床前新药钻研的全过程，蕴含药物发现、药学钻研及临床前钻研
。

From its inception in 2004, Shanghai MedicilonInc. (STAR Market stock code: 688202.SH) has been committed to providingcomprehensive research and development (R&D) services to pharmaceuticalcompanies, research institutions, and any organizations working in thepreclinical space, with the primary objective of supporting and acceleratingpharmaceutical, biopharmaceutical R&D worldwide.

联系JDB电子：

邮箱：marketing@medicilon.com.cn

电话: +86 (21) 5859-1500（总机）